Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lior Apter"'
Autor:
Lior Apter, Sarah Sharman Moser, Ashwini Arunachalam, Sivan Gazit, Moshe Hoshen, Gabriel Chodick, Nava Siegelmann-Danieli
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundTreatment for first-line (1L) metastatic non-small cell cancer (mNSCLC) changed with the introduction of immunotherapy. We describe treatment utilization and clinical outcomes in a real-world mNSCLC cohort in a 2.7-million-member state-mand
Externí odkaz:
https://doaj.org/article/fe553f1c11524f289dad65401275f32d
Autor:
Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, Josie Solomon
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 16, Iss 1, Pp 1-9 (2023)
Key points Our study found that there are substantial differences in time to reimbursement of pembrolizumab for the same conditions in different countries, with NICE and The National Advisory Committee for the Basket of Health Services in Israel appr
Externí odkaz:
https://doaj.org/article/c9081b5355fa45c7a61ae52c0c0243b7
Autor:
Yasmin Leshem, Yardena Dolev, Nava Siegelmann-Danieli, Moser Sarah Sharman, Lior Apter, Gabriel Chodick, Alla Nikolaevski-Berlin, Sivan Shamai, Ofer Merimsky, Ido Wolf
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9cf26ca914bf53a547cd50349b3f89b
https://doi.org/10.1530/endoabs.90.p379
https://doi.org/10.1530/endoabs.90.p379
Autor:
Varda Shalev, Nava Siegelmann-Danieli, Sarah Sharman Moser, Gabriel Chodick, Ashwini Arunachalam, Thomas Burke, Lior Apter
Publikováno v:
Immunotherapy. 13:851-861
Aim: We describe PD-L1 testing patterns and first-line treatment for patients with metastatic non-small-cell lung cancer in a 2.3 million-member state-mandated health service in Israel. Materials & methods: Newly diagnosed stage IV non-small-cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4e1d4fb05c6a274a4f1f70d980fb40
https://doi.org/10.2217/imt-2020-0347
https://doi.org/10.2217/imt-2020-0347
Autor:
Sarah, Sharman Moser, Shira, Yaari, Damien, Urban, Lior, Apter, Netta, Passwell, Gally, Teper, Gabriel, Chodick, Nava, Siegelmann-Danieli
Publikováno v:
Cancer Epidemiology. 79:102156
Health-care providers in the US revealed that a substantial proportion of mNSCLC patients do not receive any first-line therapy and the biggest gaps in care are time inefficiencies in the diagnostic process. The goal of this study was to determine wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0d371cdd1e418eebdaceb31d240d720
https://doi.org/10.1016/j.canep.2022.102156
https://doi.org/10.1016/j.canep.2022.102156
Autor:
Leshem, Yasmin, Dolev, Yardenna, Siegelmann‐Danieli, Nava, Sharman Moser, Sarah, BPharm, Lior Apter, Chodick, Gabriel, Nikolaevski‐Berlin, Alla, Shamai, Sivan, Merimsky, Ofer, Wolf, Ido
Publikováno v:
Cancer (0008543X); Jan2024, Vol. 130 Issue 2, p324-324, 1p
Autor:
Mirela Nadler-Milbauer, Yechezkel Barenholz, Abraham Rubinstein, Tamara Minko, Lior Apter, Sue Haupt, Ygal Haupt
Publikováno v:
Journal of Drug Targeting. 19:859-873
A novel approach to the prevention of colorectal cancer (CRC) recurrence by the local, luminal application of the combined therapies: Nutlin-3 (NUT) and the liposomal preparation of doxorubicin, Doxil(*) (Doxil) is presented here. The two drug entiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6227f35754c0060575c1ca1bc102ecb6
https://doi.org/10.3109/1061186x.2011.622401
https://doi.org/10.3109/1061186x.2011.622401